Skip to content
Phenazopyridine
Azo (phenazopyridine) is a small molecule pharmaceutical. Phenazopyridine was first approved as Azo gantanol on 1987-09-10. It is used to treat pain and urological manifestations in the USA.
Download report
Favorite
Top OTC Drugs
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenazopyridine hydrochloride
+
Sulfamethoxazole
Tradename
Company
Number
Date
Products
AZO GANTANOLRocheN-013294 DISCN1987-09-10
1 products, RLD
Hide discontinued
Phenazopyridine hydrochloride
+
Sulfamethoxazole
+
Trimethoprim
Tradename
Company
Number
Date
Products
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDEAble LaboratoriesN-021105 DISCN2001-06-26
1 products
Hide discontinued
Phenazopyridine hydrochloride
+
Sulfisoxazole
Tradename
Company
Number
Date
Products
AZO GANTRISINRocheN-019358 DISCN1990-08-31
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
good neighbor maximum strength urinary pain reliefunapproved drug other2023-06-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
urological manifestationsD020924
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
G04: Urologicals
G04B: Urologicals
G04BX: Other urologicals in atc
G04BX06: Phenazopyridine
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary retentionD016055HP_0000016R33112
Overactive urinary bladderD053201EFO_1000781N32.8111
Urge urinary incontinenceD053202EFO_0006865N39.4111
Urinary incontinenceD014549HP_0000020R3211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DysuriaD053159EFO_0003901R3022
Urinary tract infectionsD014552EFO_0003103N39.022
Postoperative painD010149G89.1811
PainD010146EFO_0003843R5211
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F0311
Cognitive dysfunctionD060825G31.8411
AgingD000375GO_0007568R41.8111
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CystoscopyD00355822
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePHENAZOPYRIDINE
INNphenazopyridine
Description
Phenazopyridine is a diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. It has a role as a local anaesthetic, a non-narcotic analgesic, a carcinogenic agent and an anticoronaviral agent. It is a diaminopyridine and an azo compound. It is a conjugate base of a phenazopyridine(1+).
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(/N=N/c2ccccc2)c(N)n1
Identifiers
PDB
CAS-ID94-78-0
RxCUI8120
ChEMBL IDCHEMBL1242
ChEBI ID
PubChem CID4756
DrugBankDB01438
UNII IDK2J09EMJ52 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 639 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,002 adverse events reported
View more details